At the news
? NEUTRALIMPACT 4/10 PRESS-RELEASE filed Nov 3, 2026 at 07:00 ET
Arvinas reported Q3 2026 revenue of $0.5M, down from $41.9M a year ago, as Pfizer collaboration revenue did not recur following the Rigel license. GAAP net loss was $53.9M ($0.82 per share) vs. consensus EPS of -$0.95, a beat on the bottom line. The company highlighted upcoming clinical data readouts for ARV-393, ARV-027, and ARV-6723 in late 2026 and 2027, and reiterated its cash runway into H2 2028.
- Q3 2026 revenue was $0.5M vs. $41.9M in Q3 2025; the decrease was driven by non-recurrence of Pfizer collaboration revenue and milestone payments.
- GAAP net loss was $53.9M ($0.82 per share) vs. consensus EPS estimate of -$0.95, a beat.
- Cash, cash equivalents, restricted cash, and marketable securities were $558.9M as of September 30, 2026, down from $685.4M at year-end 2025.
- R&D expenses decreased to $46.9M from $64.7M year-over-year, primarily due to lower external and personnel costs.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access